CHU de Liege
- Address
- lock Available on a paid plan
CHU de Liege - Gastroenterology and Oncology Research Center
CHU de Liege is a leading academic medical center conducting advanced clinical trials in immunology-based therapeutics and oncology. The center specializes in evaluating novel treatment strategies for inflammatory bowel diseases and gynecological cancers, with particular emphasis on maintenance therapies and targeted interventions that improve patient outcomes while minimizing treatment burden.
- Crohn's Disease management with innovative steroid-sparing maintenance therapies
- Platinum-sensitive recurrent ovarian cancer treatment strategies combining immunotherapy and targeted agents
- Evaluation of maintenance immunotherapies including PD-1 inhibition in solid tumors
The research program at CHU de Liege focuses on target engagement studies in inflammatory conditions and progression-free survival endpoints in oncology trials. Their expertise encompasses both early-phase safety evaluations and later-phase efficacy studies, particularly investigating combination approaches that integrate checkpoint inhibitors with novel immunomodulatory agents to optimize disease control and extend remission periods in chronic relapsing conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU de Liege
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3) | Telix Pharmaceuticals (Innovations) Pty Limited | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 4-IODOPHENYLALANINE I-131 | 1 | Unknown | 2026-03-04 | 2026-03-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.